THAOS: Gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease

Orphanet Journal of Rare Diseases

Ole B Suhr²  Pontus Karling²  Intissar Anan²  Onur N Karayal¹  Rajiv Mundayat¹  Jonas Wixner² 

[1] Pfizer Inc, New York, NY, USA;Department of Public Health and Clinical Medicine, Umeå University, Umeå S-901 87, Sweden

关键词: Transthyretin;    Quality of life;    Nutritional status;    Functional;    Gastrointestinal disorders;    Secondary;    Cardiomyopathies;    Hereditary;    Amyloidosis;    Amyloid neuropathies;    Amyloid;   

Others  :  861947
DOI  :  10.1186/1750-1172-9-61

 received in 2013-12-30, accepted in 2014-04-17,  发布年份 2014

【 摘 要 】

Background

Transthyretin amyloidosis is a systemic disorder caused by amyloid deposits formed by misfolded transthyretin monomers. Two main forms exist: hereditary and wild-type transthyretin amyloidosis, the former associated with transthyretin gene mutations. There are several disease manifestations; however, gastrointestinal complications are common in the hereditary form. The aim of this study was to explore the prevalence and distribution of gastrointestinal manifestations in transthyretin amyloidosis and to evaluate their impact on the patients’ nutritional status and health-related quality of life (HRQoL).

Methods

The Transthyretin Amyloidosis Outcomes Survey (THAOS) is the first global, multicenter, longitudinal, observational survey that collects data on patients with transthyretin amyloidosis and the registry is sponsored by Pfizer Inc. This study presents baseline data from patients enrolled in THAOS as of June 2013. The modified body mass index (mBMI), in which BMI is multiplied with serum albumin, was used to assess the nutritional status and the EQ-5D Index was used to assess HRQoL.

Results

Data from 1579 patients with hereditary transthyretin amyloidosis and 160 patients with wild-type transthyretin amyloidosis were analyzed. Sixty-three percent of those with the hereditary form and 15% of those with the wild-type form reported gastrointestinal symptoms at enrollment. Unintentional weight loss and early satiety were the most frequent symptoms, reported by 32% and 26% of those with transthyretin gene mutations, respectively. Early-onset patients (<50 years) reported gastrointestinal complaints more frequently than those with a late onset (p < 0.001) and gastrointestinal symptoms were more common in patients with the V30M mutation than in those with other mutations (p < 0.001). For patients with predominantly cardiac complications, the prevalence of gastrointestinal manifestations was not evidently higher than that expected in the general population. Both upper and lower gastrointestinal symptoms were significant negative predictors of mBMI and the EQ-5D Index Score (p < 0.001 for all).

Conclusions

Gastrointestinal symptoms were common in patients with hereditary transthyretin amyloidosis and had a significant negative impact on their nutritional status and HRQoL. However, patients with wild-type transthyretin amyloidosis or transthyretin mutations associated with predominantly cardiac complications did not show an increased prevalence of gastrointestinal disturbances.

【 授权许可】

   
2014 Wixner et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Planté-Bordeneuve V, Said G: Familial amyloid polyneuropathy. Lancet Neurol 2011, 10:1086-1097.
• [2]Olsson M, Hellman U, Planté-Bordeneuve V, Jonasson J, Lång K, Suhr OB: Mitochondrial haplogroup is associated with the phenotype of familial amyloidosis with polyneuropathy in Swedish and French patients. Clin Genet 2009, 75:163-168.
• [3]Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN: Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997, 336:466-473.
• [4]Benson MD, Kincaid JC: The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007, 36:411-423.
• [5]Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P: Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 2008, 216:253-261.
• [6]Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM: Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 2001, 276:27207-27213.
• [7]Saraiva MJ: Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett 2001, 498:201-203.
• [8]Herrick MK, DeBruyne K, Horoupian DS, Skare J, Vanefsky MA, Ong T: Massive leptomeningeal amyloidosis associated with a Val30Met transthyretin gene. Neurology 1996, 47:988-992.
• [9]Uemichi T, Uitti RJ, Koeppen AH, Donat JR, Benson MD: Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64. Arch Neurol 1999, 56:1152-1155.
• [10]Blevins G, Macaulay R, Harder S, Fladeland D, Yamashita T, Yazaki M, Hamidi Asl K, Benson MD, Donat JR: Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology 2003, 60:1625-1630.
• [11]Jin K, Sato S, Takahashi T, Nakazaki H, Date Y, Nakazato M, Tominaga T, Itoyama Y, Ikeda S: Familial leptomeningeal amyloidosis with a transthyretin variant Asp18Gly representing repeated subarachnoid haemorrhages with superficial siderosis. J Neurol Neurosurg Psychiatry 2004, 75:1463-1466.
• [12]Roe RH, Fisher Y, Eagle RC Jr, Fine HF, Cunningham ET Jr: Oculoleptomeningeal amyloidosis in a patient with a TTR Val30Gly mutation in the transthyretin gene. Ophthalmology 2007, 114:e33-37.
• [13]Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE: Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003, 10:160-184.
• [14]Suhr O, Danielsson A, Holmgren G, Steen L: Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 1994, 235:479-485.
• [15]Suhr O, Danielsson A, Rydh A, Nyhlin N, Hietala SO, Steen L: Impact of gastrointestinal dysfunction on survival after liver transplantation for familial amyloidotic polyneuropathy. Dig Dis Sci 1996, 41:1909-1914.
• [16]Suhr OB, Svendsen IH, Andersson R, Danielsson A, Holmgren G, Ranlov PJ: Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med 2003, 254:225-235.
• [17]Coelho T, Maurer MS, Suhr OB: THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013, 29:63-76.
• [18]Obayashi K, Olsson M, Anan I, Ueda M, Nakamura M, Okamoto S, Yamashita T, Miida T, Ando Y, Suhr OB: Impact of serotonin transporter and catechol-O-methyl transferase genes polymorphism on gastrointestinal dysfunction in Swedish and Japanese familial amyloidotic polyneuropathy patients. Clin Chim Acta 2008, 398:10-14.
• [19]Tashima K, Suhr OB, Ando Y, Holmgren G, Yamashita T, Obayashi K, Terazaki H, Uchino M: Gastrointestinal dysfunction in familial amyloidotic polyneuropathy (ATTR Val30Met)–comparison of Swedish and Japanese patients. Amyloid 1999, 6:124-129.
• [20]Conceição I: Clinical features of TTR-FAP in Portugal. Amyloid 2012, 19(Suppl 1):71-72.
• [21]Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon B-G, Friman S, Uchino M, Suhr OB: Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients’ survival. Liver Transpl 2009, 15:1229-1235.
• [22]Suhr OB, Herlenius G, Friman S, Ericzon BG: Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl 2000, 6:263-276.
• [23]Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, Gjertsen H, Söderdahl G, Wikström L, Ando Y, Suhr OB, Ericzon B-G: Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 2007, 7:2597-2604.
• [24]Said G, Grippon S, Kirkpatrick P: Tafamidis. Nat Rev Drug Discov 2012, 11:185-186.
• [25]Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ, Diflunisal Trial Consortium: Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013, 310:2658-2667.
• [26]Adams D: Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord 2013, 6:129-139.
• [27]Planté-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T: The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin 2013, 29:77-84.
• [28]Transthyretin-Associated Amyloidoses Outcome Survey (THAOS) - Full Text View - ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT00628745 webcite
• [29]EuroQol Group: EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990, 16:199-208.
• [30]Shaw JW, Johnson JA, Coons SJ: US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005, 43:203-220.
• [31]Agréus L, Svärdsudd K, Nyrén O, Tibblin G: The epidemiology of abdominal symptoms: prevalence and demographic characteristics in a Swedish adult population. A report from the Abdominal Symptom Study. Scand J Gastroenterol 1994, 29:102-109.
• [32]Corazziari E: Definition and epidemiology of functional gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2004, 18:613-631.
• [33]Boyce PM, Talley NJ, Burke C, Koloski NA: Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: an Australian population-based study. Intern Med J 2006, 36:28-36.
• [34]Chang F-Y, Chen P-H, Wu T-C, Pan W-H, Chang H-Y, Wu S-J, Yeh N-H, Tang R-B, Wu L, James FE: Prevalence of functional gastrointestinal disorders in Taiwan: questionnaire-based survey for adults based on the Rome III criteria. Asia Pac J Clin Nutr 2012, 21:594-600.
• [35]Dong Y-Y, Chen F-X, Yu Y-B, Du C, Qi Q-Q, Liu H, Li Y-Q: A school-based study with Rome III criteria on the prevalence of functional gastrointestinal disorders in Chinese college and university students. PLoS ONE 2013, 8:e54183.
• [36]Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A: Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In Amyloid and Amyloidosis. Amsterdam: Excerpta Medica; 1980:88-98.
• [37]Mendes Sousa M, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ: Deposition of Transthyretin in Early Stages of Familial Amyloidotic Polyneuropathy. Am J Pathol 2001, 159:1993-2000.
• [38]Saraiva MJ: Cellular consequences of transthyretin deposition. Amyloid 2003, 10(Suppl 1):13-16.
• [39]Suhr OB, Anan I, Ahlström KR, Rydh A: Gastric emptying before and after liver transplantation for familial amyloidotic polyneuropathy, Portuguese type (Val30Met). Amyloid 2003, 10:121-126.
• [40]Wixner J, Karling P, Rydh A, Hörnsten R, Wiklund U, Anan I, Suhr OB: Gastric emptying in hereditary transthyretin amyloidosis: the impact of autonomic neuropathy. Neurogastroenterol Motil 2012, 24(12):1111-e568.
• [41]Conceição I, De Carvalho M: Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 2007, 35:116-118.
• [42]Koike H, Sobue G: Late-onset familial amyloid polyneuropathy in Japan. Amyloid 2012, 19(Suppl 1):55-57.
• [43]Sousa A, Andersson R, Drugge U, Holmgren G, Sandgren O: Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered 1993, 43:288-294.
• [44]Sousa A, Coelho T, Barros J, Sequeiros J: Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995, 60:512-521.
• [45]Hellman U, Alarcon F, Lundgren H-E, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V: Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008, 15:181-186.
• [46]Whitehead WE, Borrud L, Goode PS, Meikle S, Mueller ER, Tuteja A, Weidner A, Weinstein M, Ye W: Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology 2009, 137:512-517. 517.e1–2
• [47]Aitola P, Lehto K, Fonsell R, Huhtala H: Prevalence of faecal incontinence in adults aged 30 years or more in general population. Colorectal Dis 2010, 12:687-691.
• [48]Parés D, Vial M, Bohle B, Maestre Y, Pera M, Roura M, Comas M, Sala M, Grande L: Prevalence of faecal incontinence and analysis of its impact on quality of life and mental health. Colorectal Dis 2011, 13:899-905.
• [49]Kang H-W, Jung H-K, Kwon K-J, Song E-M, Choi J-Y, Kim S-E, Shim K-N, Jung S-A: Prevalence and predictive factors of fecal incontinence. J Neurogastroenterol Motil 2012, 18:86-93.
• [50]Ikeda S, Yanagisawa N, Hongo M, Ito N: Vagus nerve and celiac ganglion lesions in generalized amyloidosis. A correlative study of familial amyloid polyneuropathy and AL-amyloidosis. J Neurol Sci 1987, 79:129-139.
• [51]El-Salhy M, Nyhlin N, Ando Y, Suhr O: The neuroendocrine system and gastrointestinal complications in patients with familial amyloidosis and polyneuropathy. Scand J Gastroenterol 1997, 32:849-854.
• [52]Yoshimatsu S, Ando Y, Terazaki H, Sakashita N, Tada S, Yamashita T, Suga M, Uchino M, Ando M: Endoscopic and pathological manifestations of the gastrointestinal tract in familial amyloidotic polyneuropathy type I (Met30). J Intern Med 1998, 243:65-72.
• [53]Nyhlin N, Anan I, El-Salhy M, Ando Y, Suhr OB: Endocrine cells in the upper gastrointestinal tract in relation to gastrointestinal dysfunction in patients with familial amyloidotic polyneuropathy. Amyloid 1999, 6:192-198.
• [54]Anan I, El-Salhy M, Ando Y, Nyhlin N, Terazaki H, Sakashita N, Suhr O: Colonic endocrine cells in patients with familial amyloidotic polyneuropathy. J Intern Med 1999, 245:469-473.
• [55]Wixner J, Obayashi K, Ando Y, Karling P, Anan I: Loss of gastric interstitial cells of Cajal in patients with hereditary transthyretin amyloidosis. Amyloid 2013, 20(2):99-106.
• [56]Steen L, Ek B: Familial amyloidosis with polyneuropathy. A long-term follow-up of 21 patients with special reference to gastrointestinal symptoms. Acta Med Scand 1983, 214:387-397.
• [57]Suhr O, Danielsson A, Steen L: Bile acid malabsorption caused by gastrointestinal motility dysfunction? An investigation of gastrointestinal disturbances in familial amyloidosis with polyneuropathy. Scand J Gastroenterol 1992, 27:201-207.